Curamys’ cell fusion technology involves the fusion of fusogenic stem cells to unhealthy cells. Similar to anti-aging concept and approach of transfusing blood from a young and healthy individual, his innovative technology is designed to revive dying cells by fusing them with healthy and young stem cells.

Curamys has identified a specific miRNA that is a key etiological factor in the pathogenesis of rare diseases including Duchenne muscular dystrophy, Lou Gehrig’s disease (i.e., amyotrophic lateral sclerosis), and nonketotic hyperglycinemia and is devoted to developing therapies leveraging this miRNA.